When ipi naive melanoma patients are given Nivolumab (or Pembrolizumab for that matter), there is roughly a 40% response rate in patients irregardless of BRAF status.
This was reported at ASCO, June 2014:
Survival,
response duration, and activity by BRAF mutation status of nivolumab
(anti-PD1, BMS-936588) and ipilimumab concurrent therapy in advanced
melanoma
Abstract LBA9003,
Sznol, Kluger, Kirkwood, Wolchok, et al
53 melanoma patients were enrolled from 2009-2012 and were given ipi
and nivo concurrently, then followed by nivo alone (with a variety of
dosing patterns). Patients with and without BRAF had similar response.
Nivolumab in previously untreated melanoma without BRAF mutation. Robert, Long, Brady, et al. N Engl J Med, November 2014.
418 previously untreated patients without the BRAF mutation were randomly assigned to Nivolumab (Opdivo) at 3mg/kg every 2 weeks or dacarbazine every three weeks. At 1 year, the overall survival rate was 72.9% in the nivo group vs 42% in the dacarbazine group. Median progression free survival was 5.1 months for the nivo group vs 2.2 months for dacarbazine. Objective response was 40% for nivo vs 13.9% for dacarbazine.
Good enough. BRAF status makes no difference in your response rate to Nivo. Now STOP giving people dacarbazine!!!!! They really are people...not just ratties!! - c
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment